CureDuchenne: Accelerating Access to Treatments of Duchenne Muscular Dystrophy
Monday, November 17, 2014
2:55 PM - 3:20 PM
CureDuchenne has collaborated with Prosensa to accelerate access to drug candidates to patients with Duchenne muscular dystrophy. The $7 million collaboration will help restart dosing of medication for patients who participated in previous clinical studies of exon skipping drugs and could help accelerate the development and potential approval timelines of four exon skipping drug candidates. This new initiative will expand CureDuchenne's relationship with Prosensa. The funding provides additional resources to Prosensa to continue working on follow-on exons in their pipeline as they focus on getting their lead compound, drisapersen, through a New Drug Application filing later this year.
Debra Miller, Founder and CEO, CureDuchenne
Bill Abernethy, Vice President, Global Market Development
View the presentation slides as a PDF